SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as the community rallies around its vision, promoting it as a cryptocurrency for the cannabis culture. There's a strong sentiment that Weedcoin embodies a movement towards natural medicine and cultural freedom, with the slogan 'Like Bitcoin, But Way Higher' gaining traction. The community is actively sharing links to its website and social media channels, emphasizing its mission to 'free the plant'.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop ($GME) is trending as traders draw comparisons to the $BYND surge, sparking discussions about a potential short squeeze. The community is analyzing GameStop's profitability, revenue from power packs, and Ryan Cohen's strategy, while also reflecting on Roaring Kitty's influence. Some investors express frustration with the stock's performance compared to other meme stocks and question Cohen's long-term vision.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending due to widespread reports of users experiencing outages and technical issues, sparking frustration and concerns about the platform's reliability; some users are unable to access their accounts or execute trades. The issues are reportedly tied to a larger Amazon Web Services (AWS) outage, but the community is still expressing distrust and considering alternative platforms. Despite the technical difficulties, the stock price is up, leading to confusion and speculation about market manipulation.

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical Inc

Intuitive Surgical is trending following quarterly earnings that beat analyst expectations, with strong revenue growth and increased adoption of the da Vinci system. The community is focused on the company's growth outlook and potential margin pressures. Discussions include the impact of procedure growth, global expansion, and the rollout of new technologies like the da Vinci 5.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla's upcoming earnings and Elon Musk's compensation plan are driving much of the current discussion. Community members are actively debating potential earnings outcomes, forward guidance, and the impact of Musk's pay package on shareholder value and stock performance. Additionally, some traders point to technical indicators and unusual options activity as potential signals for the stock's direction.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

GOOG is trending as the community discusses OpenAI's new AI browser, which is seen as a potential competitor to Google's Chrome. Some believe this poses a threat to Google's search dominance, while others argue that Google has the resources to compete and maintain its position, particularly with its AI initiatives like Gemini.

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.

Minerva Neurosciences Inc

$NERV is trending due to a significant financing deal aimed at advancing its schizophrenia treatment through Phase 3 trials, sparking excitement among retail investors. Community discussions revolve around the potential FDA catalyst and the stock's potential for further gains. The stock's substantial pre-market surge and high trading volume reflect the market's reaction to the news and the renewed focus on the company's prospects in the biotech sector.

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

GSIT is trending due to recent data showcasing the energy efficiency of its AI chips compared to GPUs, sparking discussions about its potential to disrupt the AI inference market. While some community members express concerns about a recent capital raise and potential dilution, others view it as fuel for growth and scaling production. Bullish investors are highlighting the company's valuable patents and potential for acquisition, while bears point to the company's history and cash flow.

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.

Avalo Therapeutics Inc

Avalo Therapeutics ($AVTX) is trending due to renewed community interest, possibly driven by its recent surpassing of a one-year high and BTIG adjusting their stance to a Buy rating with a target price of $40. Community members are actively discussing potential catalysts and upcoming opportunities related to the stock's momentum. The company's focus on novel therapies for immune-related diseases and recent financing updates may also contribute to the heightened attention.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending due to Q3 earnings results, which featured a miss on EPS estimates despite revenue aligning with expectations, sparking discussion around a one-time Brazilian tax issue impacting margins. Community members are debating the impact of these results on the stock's valuation and future performance, with some anticipating downgrades. Broader conversations also involve the company's content strategy and its competitive position within the streaming sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>According to a TechCrunch report, Adobe AI foundry’s custom models can produce text, images, video, and other mediums like 3D scenes.</li><li>The AI foundry is built on Adobe’s Firefly family of AI models, which were launched in 2023.</li><li>Adobe executive Hannah Elsakr said that AI foundry was launched due to the growing customer demand for deeper customization.</li></ul>Adobe (ADBE) shares rose nearly 3% in afternoon trading after the company reportedly launched its “Adobe AI Foundry” on Monday, a new product enabling businesses to collaborate with the firm in developing tailored generative AI models trained on their unique branding and intellectual property.According to a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://techcrunch.com/2025/10/20/adobe-launches-a-foundry-service-that-builds-custom-generative-ai-models-for-enteprises/">TechCrunch report</a>, Adobe AI foundry’s custom models can produce text, images, video, and other mediums like 3D scenes and are built on Adobe’s Firefly family of AI models.The report added that the Firefly models were launched in 2023 and have been trained entirely on licensed data. The foundry offering uses this service and then tailors the models for each customer using their intellectual property.Retail sentiment on Adobe remained unchanged in the ‘bullish’ territory compared to a day ago, with message volumes at ‘high’ levels, according to data from Stocktwits.<h2 class="st-heading-2">Adobe Executive’s Take On The Foundry Service</h2>Adobe’s Vice President of Generative AI New Business Ventures Hannah Elsakr told TechCrunch that the foundry service represented a natural expansion of the company’s enterprise AI products, driven by growing customer demand for deeper customization.“This is elevating a lot of the capabilities we already had,” Elsakr told TechCrunch. “The enterprise has asked us to come in and advise us, help us, partner with us, be our premier creative marketing AI partner on this,” she added.According to the report, Elsakr noted the custom models will enable brands to better effectively manage their advertising efforts. With Adobe’s tailored AI, a customer could design a single ad campaign and then easily adapt it across various seasons, languages, and formats, TechCrunch reported.“It’s highly personalized,” Elsakr said. “We’ve been talking about personalized commerce for so long, but generative AI and Firefly make it possible to put the brand in the hand of the consumer in an on-brand way.”<a href="https://stocktwits.com/symbol/ADBE">Shares of Adobe</a> have fallen over 23% this year and have declined 31% in the last 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/glass-lewis-urge-tesla-shareholders-to-vote-against-elon-musks-1-t-pay/ch6CyTCR3Yt">Glass Lewis Urges Tesla Shareholders To Vote Against Elon Musk’s $1T Pay</a>

In this photo illustration, a smartphone held in a hand shows the logo of Adobe Inc. (NASDAQ: ADBE) on September 4, 2025 in Chongqing, China. 

Adobe Stock Rises Following Reported Launch Of ‘Adobe AI Foundry’

According to a TechCrunch report, Adobe AI foundry’s custom models can produce text, images, video, and other mediums like 3D scenes.

Equity

Carvana (CVNA) stock was one of the top trending tickers on Stocktwits after the company’s shares fell nearly 6% in afternoon trading, with recent bankruptcies of subprime lender Tricolor and auto supplier First Brands Group putting the focus on auto-related firms.BTIG maintained a ‘Buy’ rating and $450 price target on Carvana, according to TheFly. The firm noted that the company's September Asset-Backed Securities performance data for its closely-watched 2025-N1 issuance has shown signs of improvement as the pace of cumulative net loss development slowed and 30- and 60-day delinquencies declined.The firm said that while it sees the September numbers as "incrementally reassuring", the environment remains dynamic. Last week, BTIG had said that with the bankruptcy of Tricolor and CarMax adding more reserves to its loan portfolio, general macro concerns have brought renewed interest in Carvana's financing exposure.Retail sentiment on Carvana dipped to ‘bearish’ from ‘neutral’ territory compared to a day ago, with message volumes at ‘normal’ levels, according to Stocktwits data.Auto supplier First Brands Group, which went bankrupt in late September, has seen its creditors open probes amid concerns over potential financial irregularities.BTIG had further noted last week that it does not believe Carvana will lose access to the securitization markets regardless of whether past securitizations experience impairment to their equity tranche. While the firm is closely following credit across consumers, it continues to see the company's fundamental value drivers as intact,&nbsp;it said.<a href="https://stocktwits.com/symbol/CVNA">Shares of Carvana</a> have gained 60% this year and have jumped over 71% in the last 12 months.Get updates to this developing story directly on Stocktwits.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/jefferies-ceo-claims-bank-was-defrauded-by-bankrupt-auto-supplier-first-brands-group/ch6sKBzR38y">Jefferies CEO Claims Bank Was ‘Defrauded’ By Bankrupt Auto Supplier First Brands Group</a>

In this photo illustration, a person holds a smartphone displaying the logo of Carvana. (Photo illustration by Cheng Xin/Getty Images)

Carvana Stock In Spotlight After 6% Slide Today: BTIG Maintains ‘Buy’ Rating

BTIG said that the company's September Asset-Backed Securities performance data for its closely-watched 2025-N1 issuance has shown signs of improvement.

American Express (AXP) CFO Christophe Le Caillec announced on Friday that the company was seeing strong engagement from Millennial and Gen Z card members, with the average number of transactions per U.S. customer about 25% higher than older cohorts.&nbsp;“Millennials and Gen Z now account for 36% of total spend, making up the same share as Gen X,” Caillec said during a post-earnings call.He added that overall spend growth continues to be driven by transaction growth, up 10% in the third quarter, a good indicator of engagement from our customer base.Retail sentiment on American Express improved to ‘extremely bullish’ territory from ‘bullish’ compared to a day ago, with message volumes at ‘high’ levels, according to data from Stocktwits.American Express stock became the top trending ticker on Stocktwits after the company’s shares rose nearly 5% in early trading. The company forecasts a 9% to 10% increase in 2025 revenue, up from the prior expectation of 8% to 10%.The firm said it now expects annual earnings per share (EPS) to be between $15.20 and $15.50, compared with the previous forecast of $15 to $15.50.American Express’ third-quarter revenue came in at $18.43 billion, compared with Wall Street estimates of $18.05 billion, according to data compiled by Fiscal AI. Its quarterly EPS were $4.14, which topped expectations of $3.98.“We saw record bookings through Amex Travel following the Platinum refresh and the launch of our new all-in-one travel app, which we introduced earlier in September in the U.S.,” said CEO Stephen Squeri.Caillec said that premium travel and expense bookings saw good momentum, with spending on front-of-cabin airline tickets up 14%. United Airlines also said on Thursday that premium cabins outperformed the main cabin once again.<a href="https://stocktwits.com/symbol/AXP">Shares of American Express</a> have jumped nearly 14% this year and have gained over 22% in the last 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/jeff-bezos-reportedly-says-people-should-be-thrilled-about-ai/ch6sOXFR38N">Jeff Bezos Reportedly Says People Should Be Thrilled About AI: ‘Don’t See How Anybody Can Be Discouraged Who Is Alive’</a>

The reported quarter marked AmEx’s tenth consecutive quarter of record revenue. 

American Express CFO Sees 25% Higher Transaction Rates Among Millennial And Gen Z Cardholders

The company forecasts a 9% to 10% increase in 2025 revenue, up from the prior expectation of 8% to 10%.

Apple’s (AAPL) Senior Vice President of Services Eddy Cue reportedly said that the sports streaming business needs fixing as the iPhone maker edges closer to securing Formula 1 rights.“We’ve gone backwards,” said Cue at the Motorsport Network’s Autosport Business Exchange&nbsp;NYC, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2025/10/16/apple-wants-to-reform-sports-streaming-as-it-nears-f1-rights-deal.html">according to a CNBC report</a>. “You used to buy one subscription, your cable subscription, and you got pretty much everything they had. Now, there’s so many different subscriptions, so I think that needs to be fixed,” Cue said during a panel&nbsp;discussion at the conference on Wednesday.The report noted that in some way, Apple could be a part of the problem as well. CNBC, citing people familiar with the matter, reported that Apple is&nbsp;set to announce its $140 million per year U.S. media rights deal with F1.Retail sentiment on Apple remained unchanged in the ‘bearish’ territory compared to a day ago, with message volumes at ‘low’ levels, according to data from Stocktwits. Shares of the company were down marginally in early trading.CNBC reported that with the F1 deal, Apple is expanding the sports line-up, which already features Major League Soccer and MLB’s “Friday Night Baseball.” An Apple TV subscription is priced at $12.99 per month.Cue noted that consumers can now access a wide variety of sports, a positive development compared to 10 or 20 years ago. However, they must sign up for “1,200 subscriptions” to do so. The solution to this, according to Cue, was “more bundling” and more partnership between media partners.“If I’m a league, and I have two partners, for example, it should be very easy for me to go between them and do all kinds of things between them and do picture-in-picture, but I can’t. And so I think that there are definitely solutions to some of these. It’s harder, but that’s why we’re all here,” Cue said at the conference, according to CNBC.<a href="https://stocktwits.com/symbol/AAPL">Shares of Apple</a> have gained nearly 7% in the last 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/nestles-us-listed-shares-rally-on-plans-to-reduce-16-000-global-jobs/ch6p3LSR3np">Nestle’s US-listed Shares Rally On Plans To Reduce 16,000 Global Jobs Over Two Years</a>

Eddy Cue speaks during Autosport Business Exchange New York, a Motorsport Network event at Classic Car Club Manhattan on October 15, 2025 in New York City.

Apple’s Eddy Cue Pushes For Fixing Sports Streaming As Company Nears Formula 1 Rights Deal

According to a CNBC report, citing people familiar with the matter, Apple is set to announce its $140 million per year U.S. media rights deal with F1.

Eli Lilly and Company (LLY) on Wednesday said that its oral GLP-1 drug Orforglipron lowered blood glucose levels in two late-stage trials, confirming its potential in treating type-2 diabetes.While one of the trials evaluated Orforglipron versus Dapagliflozin in 962 patients with type-2 diabetes inadequately controlled on Metformin, the other trial assessed Orforglipron versus placebo in 546 adults with type 2 diabetes and inadequate glycemic control with titrated insulin glargine.In both <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://lilly.mediaroom.com/2025-10-15-Lillys-oral-GLP-1,-orforglipron,-demonstrated-superior-glycemic-control-in-two-successful-Phase-3-trials,-reconfirming-its-potential-as-a-foundational-treatment-in-type-2-diabetes?utm_source=x&amp;utm_medium=organic&amp;utm_campaign=cmh_offx&amp;utm_id=cmh">trials</a>, all three doses of Orforglipron delivered significant blood sugar reduction and weight loss as well as improvements in multiple cardiovascular risk factors, the company said. While Orforglipron lowered blood sugar levels by up to 1.7% compared to 0.8% with Dapagliflozin in one trial, in the other, it lowered blood sugar by an additional 2.1% when taken with insulin glargine.In both trials, the overall safety and tolerability profile of orforglipron, as well as treatment discontinuation rates, were consistent with previous studies, Lilly said. The results of these trials will now be presented at a future medical meeting."Orforglipron has now demonstrated superiority over two active comparators in clinical trials for type 2 diabetes," said Jeff Emmick, senior vice president of product development, Lilly Cardiometabolic Health. The executive was referring to <a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-says-its-obesity-pill-topped-novo-nordisks-oral-drug-in-late-stage-diabetes-trial/chDGpSDRd6X">data</a> from another late-stage trial where Orforglipron was found to be superior to Novo Nordisk’s oral Semaglutide in treating type-2 diabetes. Emmick noted that these late-stage trial data reinforce the drug’s potential to become a new standard of care for people with type 2 diabetes.The company is now awaiting data from another late-stage trial of Orforglipron in type-2 diabetes in the first quarter of 2026.Lilly plans to submit Orforglipron for the treatment of type 2 diabetes to global regulatory agencies in 2026. Submission for the treatment of obesity is on track to occur by the end of this year, it noted.Orforglipron was discovered by Chugai Pharmaceutical Co. and licensed by Lilly in 2018. Lilly is also studying the drug as a potential treatment for obstructive sleep apnea (OSA) and hypertension in adults with obesity.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/LLY">LLY stock</a> stayed within the ‘bearish’ territory over the past 24 hours, while message volume remained at ‘low’ levels.<figure class="image"><img style="aspect-ratio:590/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_15_at_8_58_15_AM_png_d131a03bfe.webp" alt="LLY's Sentiment Meter and Message Volume as of 8:59 a.m. ET on Oct. 15, 2025 | Source: Stocktwits" width="590" height="64"><figcaption>LLY's Sentiment Meter and Message Volume as of 8:59 a.m. ET on Oct. 15, 2025 | Source: Stocktwits</figcaption></figure>LLY stock is up by 5% this year but down by about 11% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/omeros-corp-stock-soars-pre-market-after-novo-nordisk-agrees-to-buy-its-drug-candidate/ch6nwUGR3NS">Omeros Corp Stock Soars A Whopping 136% Pre-Market After Novo Nordisk Agrees To Buy Its Drug Candidate For Blood Disorder</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The entrance to the Eli Lilly factory in Kinsale, Co Cork, where weight loss drug Mounjaro is made. Picture date: Sunday May 18, 2025.

Eli Lilly Says Oral GLP-1 Drug Reduced Blood Sugar Levels In Two Late-Stage Trials

Eli Lilly plans to submit Orforglipron for the treatment of type 2 diabetes to global regulatory agencies in 2026.

Johnson &amp; Johnson (JNJ) on Tuesday announced its intent to separate its Orthopedic business.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-intent-to-separate-its-orthopaedics-business">said</a> that it will explore multiple paths to separate the business and is targeting a completion in 18 to 24 months. There can be no assurance regarding the absolute timing or structure of the proposed separation, the company stated, while adding that there can be no assurance that the transaction will be completed.The transaction, if completed, would establish a standalone orthopedics business, operating as DePuy Synthes. The company expects the transaction to increase its top-line growth and operating margins by focusing on other growth areas, such as oncology and immunology.<a href="https://stocktwits.com/symbol/JNJ">JNJ stock</a> traded nearly 1% higher in the pre-market session at the time of writing. On Stocktwits, retail sentiment around JNJ stock rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.“The planned separation reflects our long-standing commitment to portfolio optimization and value creation. We are confident that our Orthopedics business will be better positioned to improve top-line growth and operating margins as a standalone business,” CEO Joaquin Duato said. For fiscal year 2024, the Orthopedics business generated approximately $9.2 billion in sales.Johnson also appointed Namal Nawana as Worldwide President of DePuy Synthes to lead the business through the separation process. Nawana will report directly to the CEO and is expected to lead DePuy Synthes following the completion of the separation. Nawana was previously Executive Chairman and Founder of privately-held Sapphiros.Until separation, Johnson said that it will continue to operate the business in alignment with its current strategy, including continued investments.The announcement comes on the heels of the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-q3-2025-results-raises-2025-sales-outlook">reporting</a> a third-quarter (Q3) reported sales growth of 6.8% to $23.99 billion, beating an analyst estimate of $23.73 billion. The firm also reported an adjusted and diluted earnings per share (EPS) of $2.80, above the expected $2.76.Johnson &amp; Johnson also raised its full-year estimated reported sales guidance to a range of $93.0 billion to $93.4 billion, up from its previous guidance of $92.7 billion to $93.1 billion, and reaffirmed its full-year adjusted EPS guidance of $10.80 to $10.90.JNJ stock is up by 32% this week and by about 18% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/wells-fargo-appoints-ceo-charlie-scharf-as-chairman-after-q3-earnings-beat-estimates/ch6mVM6R3mE">Wells Fargo Appoints CEO Charlie Scharf As Chairman After Q3 Earnings Beat Estimates</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 Johnson and Johnson American multinational of medical, pharmaceutical and perfumery products headquartes on 28 January 2025 in Madrid, Spain.

Johnson & Johnson To Separate Its Orthopedic Business

The company said that it will explore multiple paths to separate the business and is targeting a completion in 18 to 24 months.

AbbVie (ABBV) on Monday said that the U.S. Food and Drug Administration has approved an update to the indication statement for its drug Rinvoq for the treatment of adults with moderately to severely active Inflammatory Bowel Disease.Inflammatory Bowel Disease (IBD) refers to chronic conditions that cause inflammation and swelling in the digestive tract, with the main types being Crohn's disease (CD) and ulcerative colitis (UC).Previously, RINVOQ was indicated for adults with moderately to severely active UC or CD who had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers. The updated indication statement <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://news.abbvie.com/2025-10-13-U-S-Food-and-Drug-Administration-FDA-Approves-Updated-Indication-Statement-for-RINVOQ-R-upadacitinib-for-the-Treatment-of-Inflammatory-Bowel-Disease">allows</a> the use of the drug for patients after they have received at least one approved systemic therapy in the event TNF blockers are deemed clinically inadvisable by the physician.ABBV shares rose 1% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ABBV">ABBV stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.<figure class="image"><img style="aspect-ratio:627/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_13_at_12_21_12_PM_png_ac875c34ff.webp" alt="Screenshot 2025-10-13 at 12.21.12 PM.png" width="627" height="61"><figcaption>ABBV's Sentiment Meter and Message Volume as of 12:21 p.m. ET on Oct. 13, 2025 | Source: Stocktwits</figcaption></figure> In the second quarter, Rinvoq was the second most revenue-generating drug from AbbVie’s portfolio after Skyrizi. Global Rinvoq net revenues were $2.028 billion in the three months, representing a year-over-year increase of approximately 42% on a reported basis.Rinvoq is used to treat adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, moderate to severe ulcerative colitis, and Crohn's disease, among other conditions, in the U.S. It is also approved for the treatment of children 12 years of age and older with moderate to severe eczema.Last month, AbbVie said that it does not expect any generic versions of its Rinvoq in the U.S. before April 2037 after settling litigation with all generic manufacturers that filed abbreviated new drug applications with the FDA for generic versions of Rinvoq.ABBV stock is up by 31% this year and by about 19% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sellas-life-sciences-stock-rises-on-strong-preclinical-data-for-investigational-cancer-treatment/ch6SVgiR3kU">SELLAS Life Sciences Stock Rises On Strong Preclinical Data For Investigational Cancer Treatment</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the AbbVie company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

AbbVie Stock Rises After FDA Approves Changed Recommendations For Use Of Popular Rinvoq Drug 

In the second quarter, Rinvoq was the second most revenue-generating drug from AbbVie’s portfolio after Skyrizi.

United Parcel Service (UPS) witnessed a price target cut from Citigroup to $112 from $114 ahead of the company’s third-quarter results later this month, with the firm citing a lukewarm quarter for the transportation sector.Citigroup maintained a ‘Buy’ rating, according to TheFly. The firm expects "tepid" quarters for most transportation sector companies, citing soft freight rates and unfavorable supply and demand dynamics.The ending of the de minimis exemption, a trade policy that allowed low-value imported goods to enter the United States without companies having to pay customs duties or taxes, has put pressure on parcel companies such as United Parcel Service and FedEx, and large retailers.Retail sentiment on <a href="https://stocktwits.com/symbol/UPS">United Parcel Service</a> dipped to ‘bearish’ from ‘extremely bearish’ territory a day ago, with message volumes at ‘low’ levels, according to data from Stocktwits. Shares of the company rose 0.5% in premarket trading on Monday.<figure class="image"><img style="aspect-ratio:803/100;" src="https://news.stocktwits-cdn.com/UPS_png_222c27d32f.webp" alt="UPS.png" width="803" height="100"><figcaption>UPS sentiment and message volume October 13, 2025, as of 7:25 am ET | Source: Stocktwits</figcaption></figure>The company is expected to post revenue of $20.93 billion in the third quarter and earnings per share of $1.33, according to data compiled by Fiscal AI. Last week, JPMorgan cut its price target on the stock to $85 from $96 and said that tariffs and trade policy uncertainty persisted while spot truckload rates remain subdued.In September, Bank of America had noted increased pressure on volume and costs for the company following the end of the U.S. de minimis exemption. The firm said this would also result in a muted air peak season in 2025.Shares of United Parcel Service have declined 34% this year and over 38% in the last 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/lithium-rare-earth-stocks-rally-premarket-as-us-china-trade-dispute-heats-up/ch6SQxHR3kb">TMQ, CRML, USAR: Lithium, Rare Earth Stocks Rally Premarket As US-China Trade Dispute Heats Up</a>

 In this photo illustration, a person holds a smartphone displaying the logo of United Parcel Service Inc.

UPS Stock Gets A Price Target Cut From Citigroup Amid Freight Market Softness 

Citigroup expects "tepid" quarters for most transportation sector companies, citing soft freight rates and unfavorable supply and demand dynamics.

Johnson &amp; Johnson (JNJ) has reportedly been ordered to pay $966 million to the family of a woman who died from a rare form of cancer called mesothelioma after a jury found the company liable.Mae Moore died in 2021, and her family subsequently sued the company, claiming that Johnson &amp; Johnson’s talc baby powder products contained asbestos fibers that caused her rare cancer.Reuters <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/legal/litigation/johnson-johnson-ordered-pay-966-million-after-jury-finds-company-liable-talc-2025-10-07/">reported</a> that a Los Angeles Jury has ordered the company to pay $16 million in compensatory damages and $950 million in punitive damages. The verdict could be reduced on appeal, the report added. J&amp;J stopped selling talc-based baby powder in the U.S. in 2020.JNJ is reportedly planning to appeal immediately, calling the verdict "egregious and unconstitutional." Shares of the company dropped 0.3% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/JNJ">JNJ stock</a> fell from ‘extremely bullish’ to ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:1246/122;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_07_at_1_27_04_PM_png_51213bf70d.webp" alt="JNJ's Sentiment Meter and Message Volume as of 1:27 p.m. ET on Oct. 07, 2025 | Source: Stocktwits" width="1246" height="122"><figcaption>JNJ's Sentiment Meter and Message Volume as of 1:27 p.m. ET on Oct. 07, 2025 | Source: Stocktwits</figcaption></figure>In April, a Texas judge <a href="https://stocktwits.com/news-articles/markets/equity/jnj-stock-dips-after-court-rejects-third-talc-settlement/chf3hdNRbIg">dismissed</a> J&amp;J's attempt to settle class action lawsuits related to claims of talcum powder causing ovarian cancer via a $10 billion Chapter 11 filing. The company had aimed to settle claims against its subsidiary, Red River Talc, through the bankruptcy process. It marked the company’s third attempt to resolve talc-related litigation through bankruptcy proceedings.Separately, Citi raised the price target on JNJ to $213 from $200 on Tuesday, while maintaining a ‘Buy’ rating on the shares.JNJ stock is up by 30% this year and by about 18% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/staar-surgical-long-term-shareholder-says-proposed-deal-with-alcon-undervalues-company/ch6P0tZR3hj">STAAR Surgical’s Long-Term Shareholder Says Proposed Deal With Alcon Undervalues The Company</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Johnson & Johnson logo seen displayed on a monitor. (Photo Illustration by Valera Golovniov/SOPA Images/LightRocket via Getty Images)

Johnson & Johnson Reportedly Ordered To Pay $966M To Family Of Woman Who Died Of Rare Cancer Allegedly Associated With Its Talc

According to a Reuters report, a Los Angeles Jury has ordered the company to pay $16 million in compensatory damages and $950 million in punitive damages. 

Gilead Sciences (GILD) announced on Monday that it has entered into settlement agreements with multiple players to resolve patent litigations.The company stated in a filing that it settled with generic manufacturers Lupin, Cipla, and Laurus Labs, who filed abbreviated new drug applications with the U.S. Food and Drug Administration (FDA) to market generic versions of Biktarvy.Shares of the company rose marginally at the time of writing. On Stocktwits, the retail sentiment around <a href="https://stocktwits.com/symbol/GILD">GILD stock</a> stayed within the ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.&nbsp; Under the settlements <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0000882095/000088209525000041/gild-20251006.htm">entered</a>, no generic entry is expected for Biktarvy before April 1, 2036, in the United States, Gilead said. Biktarvy was Gilead’s best-selling drug in 2024. Biktarvy sales increased 13% year-over-year to $13.4 billion for the full year 2024. The HIV drug, in fact, accounted for 47% of the company’s overall product sales in the 12 months through the end of December.Biktarvy tablets contain Bictegravir (50 mg), Emtricitabine (200 mg), and Tenofovir Alafenamide (25 mg). Wells Fargo noted that the settlement would extend the U.S. patent to April 2036 from the current December 2033. The firm believes that the Biktarvy patent expansion gives Gilead a longer runway and places it in the same bracket as AbbVie (ABBV). The firm has assigned an ‘Overweight’ rating to Gilead, with a price target of $140 per share.The price target of $140 implies a potential upside of over 24% from the stock’s closing price on Friday. GILD stock is up by 22% this year and by 34% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/amgen-to-sell-cholestrol-drug-for-approximately-60-percent-discount/ch6R3MmR3gi">Amgen To Sell Cholesterol Drug For Approximately 60% Discount</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Gilead Sciences logo is displayed on a smartphone screen, with the company's branding visible in the background, on April 20, 2025, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

Gilead Sciences Settles Patent Litigations With Generic Drugmakers For Best-Selling HIV Drug: Analyst Cheers Longer Runway

The company stated that under the settlements, no generic entry is expected for Biktarvy in the United States before April 1, 2036.

Dimensional ETF Trust - Dimensional US High Profitability ETF

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

DUHP
Dimensional ETF Trust - Dimensional US High Profitability ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest DUHP News

DUHPDimensional ETF Trust - Dimensional US High Profitability ETF